Corneal Neovascularization - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Corneal Neovascularization - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Corneal Neovascularization - Pipeline Review, H2 2014', provides an overview of the Corneal Neovascularization's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Corneal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Neovascularization and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Corneal Neovascularization
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Corneal Neovascularization and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Corneal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Corneal Neovascularization pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Corneal Neovascularization
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Corneal Neovascularization pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Corneal Neovascularization Overview 6
Therapeutics Development 7
Pipeline Products for Corneal Neovascularization - Overview 7
Pipeline Products for Corneal Neovascularization - Comparative Analysis 8
Corneal Neovascularization - Therapeutics under Development by Companies 9
Corneal Neovascularization - Therapeutics under Investigation by Universities/Institutes 10
Corneal Neovascularization - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Corneal Neovascularization - Products under Development by Companies 14
Corneal Neovascularization - Products under Investigation by Universities/Institutes 15
Corneal Neovascularization - Companies Involved in Therapeutics Development 16
Regeneron Pharmaceuticals, Inc. 16
Gene Signal International SA 17
Sirnaomics, Inc. 18
Amakem NV 19
Corneal Neovascularization - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
aganirsen - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
aflibercept - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Gene Therapy to Inhibit Vascular Endothelial Growth Factor A for Corneal Neovascularization - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
STP-601 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug to Target NOV/CCN3 for Oncology and Ophthalmology - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Gene Therapy to Activate Raver-2 Protein for Corneal Neovascularization - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AMA-0526 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drugs to Inhibit Tyrosine Kinase for Ophthalmology - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Corneal Neovascularization - Recent Pipeline Updates 40
Corneal Neovascularization - Dormant Projects 48
Corneal Neovascularization - Product Development Milestones 49
Featured News & Press Releases 49
May 12, 2014: Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularization due to inflammation, a rare eye disease with European Orphan Drug designation. 49
Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure 50
Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth 51
Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 for Diseases of the Eye 52
Sep 18, 2003: QLT Announces the Completion of Development Milestones in its Continued Efforts to Expand the Availability of Visudyne in Wet AMD Market 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Corneal Neovascularization, H2 2014 7
Number of Products under Development for Corneal Neovascularization - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Corneal Neovascularization - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 16
Corneal Neovascularization - Pipeline by Gene Signal International SA, H2 2014 17
Corneal Neovascularization - Pipeline by Sirnaomics, Inc., H2 2014 18
Corneal Neovascularization - Pipeline by Amakem NV, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Corneal Neovascularization Therapeutics - Recent Pipeline Updates, H2 2014 40
Corneal Neovascularization - Dormant Projects, H2 2014 48